CMS explains how it will negotiate the most expensive drug prices with biopharma beginning in 2026
The Centers for Medicare and Medicaid Services (CMS) late Wednesday published its first long-awaited guidance on how exactly biopharma companies will have to negotiate with the federal government when it comes to the most expensive of drugs, beginning in 2026.
The 91-page guidance document sets the requirements for manufacturers of Medicare Part D and B drugs that are selected for negotiations, and CMS is soliciting feedback, before April 14, on everything from the initial offer and counteroffer exchanges between CMS and manufacturers, how the maximum fair price (i.e. the negotiated price) will be applied across different dosage forms and strengths of a drug chosen for negotiations, as well as the process for issuing monetary penalties to those violating the new law.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.